Valuation: Incyte Corporation

Market Cap 2.4TCr 2.09TCr 1.95TCr 1.79TCr 3.37TCr 2,28800Cr 3.43TCr 23TCr 9TCr 1,14100Cr 9.02TCr 8.82TCr 3,76400Cr P/E 2026 *
52.8x
P/E 2027 * 16.5x
Enterprise Value 1.98TCr 1.72TCr 1.6TCr 1.47TCr 2.77TCr 1,88300Cr 2.82TCr 19TCr 7.4TCr 94TCr 7.42TCr 7.26TCr 3,09700Cr EV / Sales 2026 *
3.32x
EV / Sales 2027 * 2.92x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day-0.91%
1 week-0.37%
Current month-0.91%
1 month+1.34%
3 months+22.21%
6 months+17.35%
Current year+19.90%
1 week 118.02
Extreme 118.02
129.95
1 month 110.56
Extreme 110.56
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 76.45
Extreme 76.45
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
23/07/26 Free

Chief Technology Officer

15,425 0.0077%
23/07/26 Free

EVP, Head of Incyte Intl

28,921 0.0145%
16/07/26 Free

EVP & Chief Scientific Officer

46,244 0.0231%
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%-0.37%+56.67%+82.26% 2.42TCr
-0.44%+13.80%+35.85%-1.58% 7.62TCr
-0.67%-9.93%+19.77%+179.40% 4.89TCr
-4.18%+42.30%+42.30%+42.30% 4.78TCr
+2.43%+6.51%-51.95%-51.99% 4.14TCr
-0.56%+0.84%+52.95%-24.62% 3TCr
+0.58%-0.88%+99.75%-49.85% 2.19TCr
+0.23%-4.12%-7.21%+162.80% 1.92TCr
-7.35%-6.03%+64.90%+113.10% 1.71TCr
-0.16%-4.95%+68.80%+149.10% 1.57TCr
Average -1.10%-0.26%+38.18%+60.09% 3.42TCr
Weighted average by Cap. -0.92%+1.16%+31.44%+47.00%

Financials

2026 *2027 *
Net sales 594.32Cr 516.52Cr 482.23Cr 442.7Cr 834.73Cr 57TCr 849.28Cr 5.69TCr 2.23TCr 28TCr 2.23TCr 2.18TCr 93TCr 623.53Cr 541.91Cr 505.93Cr 464.45Cr 875.76Cr 59TCr 891.02Cr 5.97TCr 2.34TCr 30TCr 2.34TCr 2.29TCr 98TCr
Net income 47Cr 40Cr 38Cr 35Cr 65Cr 4.44TCr 67Cr 445.46Cr 174.47Cr 2.21TCr 174.89Cr 171.02Cr 7.3TCr 147.04Cr 127.79Cr 119.31Cr 109.53Cr 206.52Cr 14TCr 210.12Cr 1.41TCr 550.97Cr 6.99TCr 552.31Cr 540.08Cr 23TCr
Net Debt -424.92Cr -369.3Cr -344.78Cr -316.52Cr -596.81Cr -41TCr -607.21Cr -4.07TCr -1.59TCr -20TCr -1.6TCr -1.56TCr -67TCr -581.22Cr -505.14Cr -471.6Cr -432.94Cr -816.33Cr -55TCr -830.56Cr -5.56TCr -2.18TCr -28TCr -2.18TCr -2.13TCr -91TCr
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
03/26/03 $118.43 -0.91% 14,18,900
31/26/31 $119.52 -2.82% 18,30,263
30/26/30 $122.99 -3.23% 26,28,292
29/26/29 $127.10 -2.18% 29,17,698
28/26/28 $129.93 +9.30% 59,21,515
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
118.43USD
Average target price
124.26USD
Spread / Average Target
+4.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock